OPKO Health, Inc. Line of Credit Facility, Maximum Amount Outstanding During Period
OPKO Health, Inc. (OPK) reported Line of Credit Facility, Maximum Amount Outstanding During Period of $19.63 million for the 6-month period ending 2013-06-30, per its 10-Q filed 2013-08-09.
Discontinued › Notes › Debt › Line of Credit Facility
us-gaap:LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod · last filed 2013-08-09
- OPKO Health, Inc. line of credit facility, maximum amount outstanding during period for the quarter ending 2013-06-30 was $25.00K.
- OPKO Health, Inc. line of credit facility, maximum amount outstanding during period for the quarter ending 2013-03-31 was $19.60M.
- OPKO Health, Inc. line of credit facility, maximum amount outstanding during period for fiscal 2012 was $24.72M.
| Period end | Line of Credit Facility, Maximum Amount Outstanding During Period 3 month | Line of Credit Facility, Maximum Amount Outstanding During Period 6 month | Line of Credit Facility, Maximum Amount Outstanding During Period 12 month |
|---|---|---|---|
| 2013-06-30 | $25.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-09 | $19.63M 10-Q · filed 2013-08-09 | |
| 2013-03-31 | $19.60M 10-Q · filed 2013-05-10 | ||
| 2012-12-31 | $24.72M 10-K · filed 2013-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |